The FDA on October 31, 2023, approved KEYTRUDA® to be used with Gemcitabine and Cisplatin for locally advanced unresectable or metastatic Biliary Tract Cancer (BTC). KEYTRUDA® is a product of Merck & Co., Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
